Skip to main content
. 2019 Mar 15;6(Suppl 1):S34–S46. doi: 10.1093/ofid/ofy293

Table 5.

Activity of Distinct Antimicrobial Agents Tested Against 7772 Acinetobacter calcoacetiusA. baumannii Complexa Isolates Categorized as Extensively Drug-Resistant (SENTRY Program, 1997–2016)

CLSIb EUCASTb
Antimicrobial Agent MIC50, mg/L MIC90, mg/L %S %R %S %R
Amikacin >32 >32 16.0 78.2 12.4 84.0
Ampicillin-sulbactam >16 >16 9.2 76.9 c c
Cefepime >16 >16 3.6 85.9 c c
Ceftazidime >16 >16 2.4 94.1 c c
Colistin (6520)d ≤0.5 2 95.1 4.9 95.1 4.9
Gentamicin >8 >8 8.0 85.8 8.0 92.0
Imipenem >8 >8 12.8 82.6 12.8 78.2
Levofloxacin >4 >4 1.3 90.2 0.1 99.5
Meropenem >8 >8 8.1 86.3 8.1 79.6
Minocycline (5961)d 2 >8 72.7 13.6 c c
Piperacillin-tazobactam >64 >64 0.9 95.4 c c
Tigecycline (6981)d 1 4 c c c c
Tobramycin >8 >8 27.0 68.5 27.0 73.0
Trimethoprim-sulfamethoxazole >1 >1 14.7 85.3 14.7 e

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration; R, resistant; S, susceptible.

aOrganisms include A. baumannii (6), A. calcoacetiusA. baumannii complex (7756), A. nosocomialis (4), A. pittii (6).

bCLSI [28] and EUCAST [30] criteria.

cBreakpoints not determined by CLSI [28] or EUCAST [30].

dLess than 90% of isolates tested against these antimicrobials; number of isolates tested is cited in parentheses.

eDilution range did not extend high enough to determine between intermediate and R, so only the S percentage is displayed.